New drug aims to stop muscles from wasting away
NCT ID NCT07397468
First seen Feb 19, 2026 · Last updated Jun 16, 2026 · Updated 18 times
Summary
This study tests a new drug called JUV-161 to see if it can prevent muscle loss in healthy adults aged 40 to 65 who have one leg immobilized for about 6 weeks. Participants will receive weekly injections of either the drug or a placebo. The study will measure muscle changes using MRI and blood tests to check safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New Zealand Clinical Research
RECRUITINGAuckland, 1010, New Zealand
Contact Email: •••••@•••••
-
New Zealand Clinical Research
RECRUITINGChristchurch, 8011, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.